ICER

News

ICER says AZ's new hypertension drug too expensive

ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.

News

ICER says US new drug launch prices have risen sharply

ICER says the prices of new drug launches in the US rose 51% in three years, adding up to $1.5bn in first-year costs to US health systems.

News

ICER says GLP-1s 'still have serious affordability issues'

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

ICER identifies new crop of 'unsupported' drug price rises

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

Digital

FDA decision casts doubts over future of psychedelic treatme...

Psychedelic therapies have emerged as a promising frontier in mental health treatment, sparking interest from researchers and investors alike.

News

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstru

ICER says AZ's new hypertension drug too expensive

ICER says US new drug launch prices have risen sharply

ICER says GLP-1s 'still have serious affordability issues'

ICER identifies new crop of 'unsupported' drug price rises

FDA decision casts doubts over future of psychedelic treatme...

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

ICER

Editor's Picks